CONCLUSIONS	ARMYDA-4 RELOAD reveals no overall benefit from reloading patients on chronic clopidogrel therapy prior to PCI ; the benefit observed in ACS patients is a hypothesis-generating finding that needs to be confirmed by larger studies .\